Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus

NCT00763347 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

82

Enrollment

INDUSTRY

Sponsor class

Stopped Voluntarily terminated based on preliminary non-clinical findings.

Conditions

Diabetes Mellitus

Interventions

DRUG: SYR-619
DRUG: SYR-619
DRUG: SYR-619
DRUG: SYR-619
DRUG: Placebo
DRUG: Alogliptin

Sponsor

Takeda